MZL Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about MZL clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting
Phase 1

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Diffuse Large B-Cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)+6 more
Nurix Therapeutics, Inc.572 enrolled62 locationsNCT05131022
Recruiting
Phase 2

Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma

LymphomaMarginal Zone LymphomaMZL
Gottfried von Keudell, MD PhD33 enrolled1 locationNCT06510309
Recruiting
Phase 3

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

Relapsed/Refractory Follicular LymphomaRelapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
Regeneron Pharmaceuticals470 enrolled168 locationsNCT06149286
Recruiting
Phase 2

Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL

Marginal Zone Lymphoma (MZL)
The First Affiliated Hospital with Nanjing Medical University50 enrolled1 locationNCT07448324
Recruiting
Phase 1

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

DLBCL - Diffuse Large B Cell LymphomaFollicular Lymphoma ( FL)Mantle Cell Lymphoma (MCL)+2 more
LTZ Therapeutics, Inc.42 enrolled5 locationsNCT07121946
Recruiting

Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms

Diffuse Large B-Cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Follicular Lymphoma ( FL)+3 more
iOMEDICO AG2,950 enrolled1 locationNCT06043011
Recruiting
Phase 2

Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.

Marginal Zone Lymphoma (MZL)
The First Affiliated Hospital of Soochow University23 enrolled1 locationNCT07372365
Recruiting
Phase 4

Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma

Marginal Zone Lymphoma (MZL)
Beijing Tongren Hospital88 enrolled3 locationsNCT07355699
Recruiting
Phase 2

Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL

Marginal Zone Lymphoma (MZL)
The First Affiliated Hospital with Nanjing Medical University169 enrolled1 locationNCT07208981
Recruiting
Phase 2

Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL: A Randomized, Open Phase II Trial

Marginal Zone Lymphoma (MZL)
Fei Li90 enrolled1 locationNCT06700798
Recruiting
Phase 2

Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma

Marginal Zone Lymphoma (MZL)
Second Affiliated Hospital, School of Medicine, Zhejiang University51 enrolled18 locationsNCT07022223
Recruiting
Phase 1

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

Diffuse Large B-Cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)+5 more
Nurix Therapeutics, Inc.248 enrolled16 locationsNCT04830137
Recruiting

Study to Assess Effectiveness and Safety of Zanubrutinib for Patients With Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)

Marginal Zone Lymphoma (MZL)
IRCCS Azienda Ospedaliero-Universitaria di Bologna59 enrolled15 locationsNCT06823960
Recruiting

REal World Data in LYmphoma and Survival in Adults

Follicular Lymphoma ( FL)Mantle Cell Lymphoma (MCL)Marginal Zone Lymphoma (MZL)+4 more
Hospices Civils de Lyon6,000 enrolled37 locationsNCT03869619